Cargando…

The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells — A data description

A large number of breast cancers are characterized by amplification and overexpression of the chromosome segment surrounding the HER2 (ERBB2) oncogene. As the HER2 amplicon at 17q12 contains multiple genes, we have systematically explored the role of the HER2 co-amplified genes in breast cancer cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hongisto, Vesa, Aure, Miriam Ragle, Mäkelä, Rami, Sahlberg, Kristine Kleivi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Data in Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536024/ https://www.ncbi.nlm.nih.gov/pubmed/26484103 http://dx.doi.org/10.1016/j.gdata.2014.06.025

Ejemplares similares

MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
por: Normann, Lisa Svartdal, et al.
Publicado: (2021)

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
por: Normann, Lisa Svartdal, et al.
Publicado: (2023)

miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
por: Normann, Lisa Svartdal, et al.
Publicado: (2022)

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
por: Jernström, Sandra, et al.
Publicado: (2017)

High-Throughput 3D Screening Reveals Differences in Drug Sensitivities between Culture Models of JIMT1 Breast Cancer Cells
por: Hongisto, Vesa, et al.
Publicado: (2013)

miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
por: Lindholm, Evita Maria, et al.
Publicado: (2019)

miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer
por: Ben-Elazar, Shay, et al.
Publicado: (2021)

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
por: Liu, Yunhua, et al.
Publicado: (2018)

Identifying In-Trans Process Associated Genes in Breast Cancer by Integrated Analysis of Copy Number and Expression Data
por: Aure, Miriam Ragle, et al.
Publicado: (2013)

Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset
por: Pobiruchin, Monika, et al.
Publicado: (2016)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
por: Moss, Nelson S., et al.
Publicado: (2023)

Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
por: Nunes-Xavier, Caroline E., et al.
Publicado: (2016)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
por: Schram, Alison M., et al.
Publicado: (2022)

HER2 Expression in Peritoneal Dissemination of High-Grade Serous Ovarian Carcinoma: A Comparative Study of Immunohistochemical Reactivity Using Four HER2 Antibodies
por: Yeo, Min-Kyung, et al.
Publicado: (2022)

Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
por: Maoz, Myriam, et al.
Publicado: (2019)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
por: Aure, Miriam Ragle, et al.
Publicado: (2015)

Bacterial tag encoded FLX titanium amplicon pyrosequencing (bTEFAP) based assessment of prokaryotic diversity in metagenome of Lonar soda lake, India
por: Dudhagara, Pravin, et al.
Publicado: (2015)

Adenocarcinoma Arising in an Ectopic Hamartomatous Thymoma with HER2 Overexpression
por: Oh, Harim, et al.
Publicado: (2019)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Data on 2D culture characterisation of potential markers in human HER2-positive breast cancer cell lines
por: Pham, Son H., et al.
Publicado: (2023)

Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas
por: Yamamoto, Hiromasa, et al.
Publicado: (2013)

Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
por: de Souza, Ana Amélia, et al.
Publicado: (2019)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
por: Auliac, Jean-Bernard, et al.
Publicado: (2019)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer
por: Schulz, R, et al.
Publicado: (2014)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk
por: Katz, E, et al.
Publicado: (2010)

Author Correction: Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
por: Maoz, Myriam, et al.
Publicado: (2020)

Towards establishing extracellular vesicle-associated RNAs as biomarkers for HER2+ breast cancer
por: Hisey, Colin L., et al.
Publicado: (2021)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5jort8t1k3t7for1014qlh3d5e